MedTrace Logo

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

NCT02282137 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2020-08-19

No results posted yet for this study

Summary

This is a phase II clinical trial study to show how well the 68Ga-PSMA-11 (ProstaMedix™) PET-CT scan works in detecting tumor location and size in patients with suspected or confirmed prostate cancer, as well as prostate cancer that may have come back in patients with elevated PSA ( a prostate-specific antigen tumor marker) after initial treatment.

Conditions

Interventions

DRUG

68Ga-PSMA

Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.

Sponsors & Collaborators

  • Radiomedix, Inc.

    collaborator INDUSTRY

  • Excel Diagnostics and Nuclear Oncology Center

    collaborator OTHER

  • Ebrahim Delpassand

    lead OTHER

Principal Investigators

  • Rodolfo Nunez, MD · Excel Diagnostics and Nuclear Oncology Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02282137 on ClinicalTrials.gov